Corpus Intelligence IC Memo — NYU LANGONE HOSPITALS 2026-04-26 05:02 UTC
IC Memo — NYU LANGONE HOSPITALS
Investment Committee Memorandum | NY | 1618 beds | Grade C | EBITDA uplift $533.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

NYU LANGONE HOSPITALS

CCN 330214 | NEW YORK, NY | 1618 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

NYU LANGONE HOSPITALS is a 1618-bed large academic medical center in NEW YORK, NY with $7.24B in net patient revenue and a -7.8% operating margin. The hospital serves a payer mix of 28.0% Medicare, 6.7% Medicaid, and 65.3% commercial.

Thesis: Undervalued. Our ML models identify $533.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -7.8% to -0.5% (+736bps).

Net Revenue HCRIS$7.24B
Current EBITDA COMPUTED$-567.9M
Operating Margin COMPUTED-7.8%
Occupancy HCRIS86.5%
Revenue / Bed COMPUTED$4.5M
Net-to-Gross HCRIS17.5%
Distress Probability ML39.4%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
68
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -7.8% places it above the state median. Among 68 size-comparable peers (809-3236 beds), the median margin is -5.9%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (809-3236), prioritizing same-state peers. 68 hospitals in the comp set.

HospitalStateBedsRevenueMargin
NYU LANGONE HOSPITALS (Target)NY1618$7.24B-7.8%
NEW YORK PRESBYTERIAN HOSPITALNY2850$7.69B-1.4%
CLEVELAND CLINIC HOSPITALOH1326$6.38B-17.7%
VANDERBILT UNIVERSITY MEDICAL TN1084$5.44B-15.9%
UCSF MEDICAL CENTERCA834$5.44B-5.4%
ADVENTHEALTH ORLANDOFL2738$5.40B2.5%
UNIV OF MI HOSPITALS & HLTH CTMI951$4.62B-1.4%
CEDARS-SINAI MEDICAL CENTERCA908$3.92B-5.5%
INDIANA UNIVERSITY HEALTHIN1269$3.58B-38.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $533.0M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$152.1M+210bp18mo
Cost to Collect4.5%2.5%$144.8M+200bp12mo
Denial Rate Reduction12.0%6.5%$143.4M+198bp12mo
A/R Days Reduction5200.0%3800.0%$88.1M+122bp9mo
Clean Claim Rate88.0%96.0%$4.6M+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$152.1M
Cost to Collect
$144.8M
Denial Rate Reduction
$143.4M
A/R Days Reduction
$88.1M
Clean Claim Rate
$4.6M
Total EBITDA Uplift$533.0M
Current EBITDA$-567.9M
+ RCM Uplift+$533.0M
Pro Forma EBITDA$-34.9M
Current Margin-7.8%
Pro Forma Margin-0.5%
WC Released (1x)$277.7M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-873.7M$1.58B0.00x-100.0%
Base (11x exit)10.0x11.0x$-873.7M$1.46B0.00x-100.0%
Bull Case9.0x11.0x$-786.3M$2.93B0.00x-100.0%
Bull (12x exit)9.0x12.0x$-786.3M$2.97B0.00x-100.0%
Bear Case11.0x10.0x$-961.1M$-797.4M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-961.1M$-1.19B0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 68 hospitals with 809-3236 beds
  • Same-state prioritization (n=7)
  • Comp margins: P25=-18.0% / P50=-5.9% / P75=2.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.